Get started
Author

Saira Khalique

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
2020 · Timothy A. Yap, Brent O’Carrigan, et al. · Journal of Clinical Oncology · 259
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 83
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
2022 · David J Pinato, Daniela Ferrante, et al. · The Lancet Oncology · 81
PDF
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
2018 · Saira Khalique, Kalnisha Naidoo, et al. · The Journal of Pathology Clinical Research · 76
PDF
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
2021 · Susana Banerjee, James Stewart, et al. · International Journal of Gynecological Cancer · 69
PDF
Translational genomics of ovarian clear cell carcinoma
2019 · Saira Khalique, Christopher J. Lord, et al. · Seminars in Cancer Biology · 51
PDF
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
2018 · Peter Barry, Alexandra Vatsiou, et al. · Clinical Cancer Research · 43
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
2023 · Alessio Cortellini, Josep Tabernero, et al. · The Lancet Oncology · 35
PDF
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
2022 · David J. Pinato, Daniela Ferrante, et al. · European Journal of Cancer · 31
PDF
Nintedanib in ovarian cancer
2017 · Saira Khalique, Susana Banerjee · Expert Opinion on Investigational Drugs · 30
Maintenance therapy in ovarian cancer
2014 · Saira Khalique, Jane M. Hook, et al. · Current Opinion in Oncology · 27
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma
2021 · Saira Khalique, Sarah Nash, et al. · Cancers · 22
PDF
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry
2022 · Alessio Cortellini, Alessandra Gennari, et al. · JNCI Journal of the National Cancer Institute · 20
PDF
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
2016 · Eamonn Morrison, Patty Wai, et al. · Journal of Visualized Experiments · 19
PDF
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma
2025 · James Stewart, Dragomir B. Krastev, et al. · Oncogene · 18
PDF
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma ( HNSCC ) in the UK
2024 · Ifigenia Vasiliadou, Derek Grose, et al. · International Journal of Cancer · 10
PDF
Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting
2023 · Zena Alizzi, Patricia Roxburgh, et al. · Journal of Clinical Medicine · 10
PDF
Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR
2019 · Saira Khalique, Stephen J Pettitt, et al. · The Journal of Pathology Clinical Research · 9
PDF
Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes
2023 · Zena Alizzi, Sayeh Saravi, et al. · International Journal of Gynecological Cancer · 7
PDF
Clinical Pharmacists: An Invaluable Part of the Coronavirus Disease 2019 Frontline Response
2020 · Nadia C. Ferguson, Nicholas J. Quinn, et al. · Critical Care Explorations · 7
Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis‐related ovarian cancers‡
2022 · Saira Khalique, Sarah Nash, et al. · The Journal of Pathology · 5
ROSELLA (GOG3073, engotov72, APGOT-OV10): a phase 3 study of relacorilant + nab-paclitaxel in patients with platinum-resistant ovarian cancer
2026 · Domenica Lorusso, Stanislas Quesada, et al. · International Journal of Gynecological Cancer · 2
PO-457 Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
2018 · S. Khalique, K. Naidoo, et al. · ESMO Open · 2
A sinGle-arm phase II study to assess efficacy, tOxicity, and quAlity of life following 27Gy in 6 fractions palliative intensity modulated radiotherapy with early integration of palliative care (GOAL27-6)
2026 · Kevin Chiu, Amit Gupta, et al. · Radiotherapy and Oncology · 1
Palliative Radiotherapy with 27 Gy in 6 Fractions for Head and Neck Cancer: A Single-Centre Experience of Toxicities and Clinical Outcomes
2026 · Amani A Chowdhury, Amit Gupta, et al. · Radiotherapy and Oncology · 1
Works count: 51
Citation count: 912
H-index: 15
I10-index: 17
Year
Topic
Type